Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective January 13, 2025 AUSTIN, Texas , Jan. 10, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its name to Rein Therapeutics, Inc. The new name, logo, website, and branding elements reflect the Company's mission to develop first-in-class treatments to rein in diseases. The Company's common stock will begin trading under the Nasdaq ticker symbol "RNTX" effective January 13, 2025.
